The relationship between FV Leiden and pulmonary embolism

Respiratory Research

Christine De Staercke¹  W Craig Hooper¹ 

[1] Hematologic Disease Branch, Division of AIDS, STD, and TB Laboratory Research, National Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, USA

关键词: venous thrombosis;    pulmonary embolism;    genetics;    FV Leiden;   

Others  :  1227412
DOI  :  10.1186/rr180

 received in 2001-04-24, accepted in 2001-08-21,  发布年份 2001

【 摘 要 】

Pulmonary embolism (PE) is one of the leading causes of in-patient hospital deaths. As a consequence, the identification of hemostatic variables that could identify those at risk would be important in reducing mortality. It has previously been thought that deep vein thrombosis and PE are a single disease entity and would, therefore, have the same risk factors. This view is changing, however, with the realization that the prevalence of FV Leiden, a recognized genetic risk factor for deep vein thrombosis, may be a 'milder' genetic risk factor for PE. These observations suggest that PE is not only associated with a different set of risk factors, but may be reflective of a different clot structure.

【 授权许可】

   
2002 BioMed Central Ltd

【 参考文献 】

• [1]Anderson FA, Wheeler B, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE: A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991, 151:933-938.
• [2]De Stefano V, Chiusolo P, Paciaroni K, Leone G: Epidemiology of factor V Leiden: clinical implications. Seminar Thromb Hemost 1998, 24:367-379.
• [3]Price DT, Ridker PM: Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective. Ann Intern Med 1997, 127:895-903.
• [4]Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B: Activated protein C resistance caused by Arg506Gln mutation in Va. Lancet 1994, 343:1361-1362.
• [5]Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Driven RJ, de Rhonde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
• [6]Rosen SB, Sturk A: Activated protein C resistance: a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem 1997, 35:501-516.
• [7]Hooper WC, Evatt BL: The role of activated protein C resistance in the pathogenesis of venous thrombosis. Am J Med Sci 1998, 316:120-128.
• [8]Ridker PM, Miletich JP, Hennekens CH, Buring JE: Ethnic distribution of Factor V leiden in 4047 men and women. Implications for venous thrombosis screening. JAMA 1997, 277:1305-1307.
• [9]Hooper WC, Dilley A, Ribeiro MJA, Benson J, Austin H, Silva V, Wenger NK, Rawlins PA: Racial difference in the prevalence of the Arg506→Gln mutation. Thromb Res 1996, 81:577-581.
• [10]Manten B, Westendorp RGJ, Koster T, Reistma PH, Rosendaal FR: Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: A focus on the factor V Leiden mutation. Thromb Haemost 1996, 76:510-513.
• [11]Martinelli I, Cattaneo M, Panzeri D, Mannucci PM: Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997, 77:440-443.
• [12]Turkstra F, Karemaker R, Kuijer PMM, Prins MH, Buller HR: Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different ? Thromb Haemost 1999, 81:345-348.
• [13]Vandenbroucke JP, Bertina RM, Holmes ZR, Spaargaren C, Van Krieken JHJM, Manten B, Reitsma PH: Factor V Leiden and fatal pulmonary embolism. Thromb Haemost 1998, 79:511-516.
• [14]Dunn ST, Trong S: Evaluation of role of Factor V Leiden mutation in fatal pulmonary thromboembolism. Thrombosis Res 1998, 91:7-14.
• [15]Gorman TE, Arcot A, Baker P, Prior TW, Brandt JT: Prevalence of the factor V Leiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for Factor V Leiden detection. Am J Clin Pathol 1999, 111:413-417.
• [16]Slovacek KJ, Harris AF, Greene JF, Rao A: Fatal pulmonary embolism: A study of genetic and acquired factors. Molec Diag 2000, 5:53-58.
• [17]Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3'-untranslated region of the pro-thrombin gene is associated with elevated plasma prothrom-bin levels and an increase in venous thrombosis. Blood 1996, 88:3698-3703.
• [18]Meyer G, Emmerich J, Helley D, Arnaud E, Nicaud V, Alhenc-Gelas M, Aiach M, Fischer A-M, Sors H, Fiessinger JN: Factors V Leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med 2001, 110:12-15.
• [19]Margaglione M, Brancaccio V, De Lucia D, Martinelli M, Ciampa A, Grandone E, Di Minno G: Inherited thrombophilic risk factors and venous thromboembolism. Chest 2000, 118:1405-1411.
• [20]Kohlmeier RE, Cho CG, Bux RC, Guerra L, Rulon JJ, Selby DM, Gulley ML: Prothrombin gene mutation uncommon in pulmonary embolism. South Med J 2000, 93:1073-1077.
• [21]Bounameaux H: Factor V Leiden paradox: risk of deep vein thrombosis but not of pulmonary embolism. Lancet 2000, 356:182-183.
• [22]Bjorgell O, Nilsson PE, Nilsson J-A, Svensson PJ: Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation. Thromb Haemost 2000, 83:648-651.
• [23]Moser KM, Lemoine JR: Is embolic risk conditioned by location of deep venous thrombosis? Ann Int Med 1981, 94:439-444.